Adenine base editing to treat progeria syndrome and extend the lifespan

References

[1] Gordon LB,D’Agostino RB Sr.Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.Circulation2014;130:27-34 PMCID:PMC4082404

[2] Puttaraju M,Klein S.Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome.Nat Med2021;27:526-35

[3] Erdos MR,Tavarez UL.A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome.Nat Med2021;27:536-45

[4] Beyret E,Yamamoto M.Single-dose CRISPR-Cas9 therapy extends lifespan of mice with Hutchinson-Gilford progeria syndrome.Nat Med2019;25:419-22 PMCID:PMC6541418

[5] Santiago-Fernández O,Quesada V.Development of a CRISPR/Cas9-based therapy for Hutchinson-Gilford progeria syndrome.Nat Med2019;25:423-6 PMCID:PMC6546610

[6] Anzalone AV,Liu DR.Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.Nat Biotechnol2020;38:824-44

[7] Koblan LW,Wilson C.In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice.Nature2021;589:608-14 PMCID:PMC7872200

[8] Musunuru K,Mizoguchi T.In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.Nature2021;593:429-34